What Chimera Research Group does

Chimera Research Group, Inc. is a privately held, subscription-based equity research firm founded in 2011 and operating under the laws of New Jersey, with its website indicating a San Francisco base. The company provides independent investment and trading ideas for the biotech and pharmaceutical sectors, covering both early-stage companies with impending FDA decisions or clinical trial results and mid-to-large-cap bio-pharma names with specific catalysts. Its product portfolio spans Research Reports, Trade Reports, Daily Updates, Charts and Technical Analysis, a Members-only Forum, and real-time alerts distributed via Twitter and email; premium add-ons include Direct Email access, disclosure of the team's own trades, and multi-year Biotech M&A Deal Databases (2018-2025). All research is conducted without compensation from covered companies, with personal holdings disclosed to subscribers.

The firm employs a small, multidisciplinary team — Research Analysts Jason Chew (former oncology drug discovery researcher at Telik and Exelixis) and David Sobek (PhD, contributing columnist for TheStreet.Com and Seeking Alpha), and Biotech Trading Analyst Joe Gantoss (28 years of technical analysis experience) — collectively bringing over 50 years of combined biotech and pharma expertise. Chimera's go-to-market is a content-led, self-serve subscription model priced at $99/month, $249/quarter, and $850/year (with a 7-day free trial on annual plans), supported by a freemium blog funnel, earned media coverage in outlets such as Yahoo Finance, NASDAQ, and FierceBiotech, and owned social channels on Twitter, StockTwits, and LinkedIn. The customer base spans institutional investors (hedge funds, venture capitalists), pharma industry professionals (executives, physicians, scientists), and retail/self-directed investors, with no enterprise-anchor or large-contract revenue concentration evident from the available data.

Name

Chimera Research Group

Legal name

Chimera Research Group, Inc.

Website

https://chimeraresearchgroup.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Chimera Research Group is a privately held, subscription-based independent equity research service founded in 2011 that delivers biotech and pharmaceutical investment ideas, trade reports, technical analysis, and real-time alerts to institutional, professional, and retail investors.

Ownership category

akta.pro rank

Product category

Biotech Equity Research

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Equity Research (FSACAGAA)

akta.pro secondary industry

Industry & Sector Research (Syndicated/Custom) (BPAHALAE)

Keywords

• Biotech equity research
• Pharmaceutical investment analysis
• Clinical trial research
• Biotech trading reports
• Technical analysis charts

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Subscription Services: The primary revenue stream is subscription-based access to premium research content including daily updates, trade reports, research reports, charts and technical analysis, and access to a members-only forum. Subscribers pay recurring fees at monthly, quarterly, or annual intervals.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Chimera Research Group delivers a subscription-based equity research service for the biotech and pharmaceutical sectors, providing independent, actionable investment and trading ideas backed by comprehensive fundamental research. Coverage focuses on early-stage companies with impending FDA decisions or clinical trial results and on mid-to-large-cap bio-pharma companies with specific catalysts. Subscribers receive access to Research Reports, Trade Reports, Daily Updates, Charts & Technical Analysis, Real-Time Twitter/email alerts, and a Members-Only Forum that includes contributions from major biotech hedge fund managers and pharmaceutical executives.

Product overview

Chimera Research Group is a subscription-based equity research service for the biotech and pharmaceutical sectors, providing independent investment and trading intelligence. The company offers a unified platform of six integrated service modules: Research Reports covering clinical trials and competitive analysis, Trade Reports with risk-reward optimization, Daily Updates on sector news, Charts & Technical Analysis with entry/exit points, a Members-only Forum with contributions from hedge fund managers and pharma executives, and Real-Time Updates via Twitter and email alerts. Premium features include access to the team's own trade positions and direct analyst communication. The company was founded in 2011 and focuses on early-stage companies with FDA decisions or clinical trial catalysts.

Differentiator

Problem solved

Functional benefit

Products and services

• Research Reports Peer-reviewed fundamental research reports covering clinical trials, pipelines, and competitive landscapes of biotech and pharmaceutical companies, produced for subscribing investors and industry professionals.
• Trade Reports Investment and trade analyses providing risk-reward profiles and entry/exit strategies using statistical, scientific, fundamental, and technical analysis, targeted at active biotech stock traders.
• Daily Update Daily news and development coverage of the biotech and pharmaceutical sectors delivered to subscribers as part of the Chimera Research Group subscription.
• Charts and Technical Analysis Technical analysis reports with step-by-step chart walkthroughs that mark technical entry and exit points and key support lines for biotech and pharmaceutical stocks.
• Members-Only Forum Private online community where subscribers interact with Chimera Research Group founders, analysts, and guest contributors, including hedge fund managers from major biotech hedge funds and pharmaceutical executives.
• Real-Time Updates Service Real-time Twitter feed and email alert service providing instant communication of breaking news and biotech/pharma developments to subscribers.
• Biotech M&A Deal Database Standalone premium database tools tracking biotech mergers and acquisitions deals across multiple years (2018-2025), accessible to Chimera Research Group subscribers.

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• InvestorsObserver: Online research and analytics platform providing stock ratings and trade ideas to retail investors — adjacent in delivering actionable trade recommendations at consumer price points.
• TipRanks: Analyst-rating aggregation and transparency platform serving retail investors; partially overlapping with Chimera's transparency-focused value prop (Team Trades disclosures).

Broad incumbents

• TheStreet: Financial news and commentary site where David Sobek writes a weekly biotech column — overlap in financial commentary audience and biotech coverage angle.
• Seeking Alpha: Largest crowdsourced investment research publishing platform where Chimera's own analysts (Jason Chew, David Sobek, Joe Gantoss) contribute — overlapping content and audience, but free/contributor-led rather than subscription-led.
• Morningstar: Broad investment research and data powerhouse serving institutional and retail investors with analyst reports and ratings — overlapping investment-advice category but much wider mandate.

Direct peers

• Hedgeye Risk Management: Subscription-based investment research platform with paid tiers, daily notes, and proprietary analyst views — comparable subscription research/business model to Chimera.
• Argus Research: Independent equity research provider delivering fundamental analysis and reports to institutional and individual investors — a direct comparable in research-as-a-service.
• Cabot Wealth Network: Subscription investment advisory publisher with sector-focused newsletters and paid tiers — comparable independent retail-investor research subscription model.
• Zacks Investment Research: Subscription-based equity research firm offering stock analysis, rankings, and premium tiers — directly comparable to Chimera's paid research/reports subscription model.
• The Motley Fool: Subscription investment research service with tiered memberships and stock recommendations, similar in pricing structure and retail-investor GTM to Chimera.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/chimeraresearch
• LinkedInlinkedin.com/company/chimaera-research-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chimera Research Group